Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

To join this study, you would need to have triple-negative breast cancer that has been confirmed by special tests. You should also have had chemotherapy before your surgery (neoadjuvant treatment) and still had some cancer cells found after your operation. Importantly, there should be no signs that the cancer has spread to other parts of your body or come back where it was before.

Your surgery must have successfully removed all visible cancer in your breast and/or lymph nodes, and you should be recovering well from it. You must also be able to continue receiving pembrolizumab, which is part of the standard care after neoadjuvant treatment. There's a time limit for joining: you need to be enrolled within 16 weeks of your surgery. If you've had radiotherapy, you must have completed it and recovered before joining.

If you decide to take part in this study, you will be assigned by chance (like flipping a coin) to receive either the new drug combination (sacituzumab tirumotecan plus pembrolizumab) or the doctor's choice of standard care, which could be pembrolizumab alone or with capecitabine. Neither you nor your doctor will get to choose which group you are in. You will have regular visits to the clinic for treatments, check-ups, blood tests, and scans to monitor how you are doing and to check for any side effects.

The treatments will be given over a period of time, and the doctors will explain the schedule for your specific treatment group. There will be ongoing follow-up appointments even after your main treatment period finishes, to keep a close eye on your health and check if the cancer returns. The total duration of your involvement, including follow-up, will be determined by the study design and your personal progress, and your study team will provide more specific details.